Stoke Therapeutics (NASDAQ:STOK) Earns "Buy" Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK - Free Report) in a report issued on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $22.00 target price on the stock.

STOK has been the subject of several other research reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. Finally, Chardan Capital assumed coverage on shares of Stoke Therapeutics in a research report on Friday, December 20th. They issued a "buy" rating and a $24.00 price target for the company. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $23.00.

Stoke Therapeutics Stock Down 4.7 %

Stoke Therapeutics stock traded down $0.41 during mid-day trading on Tuesday, hitting $8.33. 1,043,541 shares of the stock were exchanged, compared to its average volume of 879,028. The stock has a market capitalization of $441.24 million, a price-to-earnings ratio of -3.97 and a beta of 0.95. Stoke Therapeutics has a 12 month low of $5.21 and a 12 month high of $17.58. The firm's fifty day simple moving average is $10.62 and its two-hundred day simple moving average is $12.32.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,170 shares of the firm's stock in a transaction on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $78,852.60. Following the transaction, the chief executive officer now directly owns 68,671 shares in the company, valued at approximately $877,615.38. This trade represents a 8.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Jonathan Allan sold 9,696 shares of the firm's stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $123,914.88. Following the transaction, the general counsel now owns 35,142 shares in the company, valued at approximately $449,114.76. This trade represents a 21.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 62,849 shares of company stock worth $809,421. Corporate insiders own 11.30% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds have recently made changes to their positions in the business. KLP Kapitalforvaltning AS bought a new stake in shares of Stoke Therapeutics during the 4th quarter worth $63,000. Teacher Retirement System of Texas bought a new stake in shares of Stoke Therapeutics during the 4th quarter worth $113,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Stoke Therapeutics during the 4th quarter worth $124,000. Tower Research Capital LLC TRC raised its stake in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock worth $132,000 after purchasing an additional 4,918 shares during the period. Finally, Invesco Ltd. bought a new stake in shares of Stoke Therapeutics during the 4th quarter worth $133,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.